Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Navidea Biopharmaceuticals Inc (NY: NAVB ) N/A UNCHANGED Last Price Updated: 8:00 PM EDT, Oct 5, 2023 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Navidea Biopharmaceuticals Inc < Previous 1 2 3 4 5 6 Next > 12 Health Care Stocks Moving In Tuesday's Pre-Market Session March 14, 2023 Via Benzinga 12 Health Care Stocks Moving In Monday's After-Market Session March 13, 2023 Via Benzinga Why Horizon Global Shares Are Trading Higher By Over 340%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session January 03, 2023 Gainers Horizon Global Corporation (NYSE: HZN) shares surged 341% to $1.7161 after the company announced it will be acquired by First Brands Group. Via Benzinga Navidea Biopharmaceuticals Announces the Notice of Allowance for U.S. Patent Application for Key Component of the Company’s Cancer Immunotherapy Pipeline January 03, 2023 From Navidea Biopharmaceuticals, Inc. Via Business Wire Why Silo Pharma Shares Are Trading Higher By Around 64%? Here Are 46 Stocks Moving In Friday's Mid-Day Session December 30, 2022 Gainers Dermata Therapeutics, Inc. (NASDAQ: DRMA) shares jumped 121% to $0.4428 after the company requested to withdraw its registration on Form S-1 and said it does not intend to pursue the... Via Benzinga Navidea Biopharmaceuticals Files Appeal in CRG Case November 30, 2022 From Navidea Biopharmaceuticals, Inc. Via Business Wire Navidea Biopharmaceuticals Announces 50th Participant Enrolled in the Company’s Phase 3 Trial in Rheumatoid Arthritis November 28, 2022 From Navidea Biopharmaceuticals, Inc. Via Business Wire CORRECTING and REPLACING Navidea Biopharmaceuticals Reports Third Quarter 2022 Financial Results November 14, 2022 From Navidea Biopharmaceuticals, Inc. Via Business Wire Navidea Biopharmaceuticals Announces Details of Presentation at Upcoming Society for Immunotherapy of Cancer Annual Meeting November 07, 2022 From Navidea Biopharmaceuticals, Inc. Via Business Wire Stocks That Hit 52-Week Lows On Friday November 04, 2022 Friday's session saw 236 companies set new 52-week lows. Via Benzinga Navidea Biopharmaceuticals to Host Third Quarter 2022 Earnings Conference Call and Business Update November 04, 2022 From Navidea Biopharmaceuticals, Inc. Via Business Wire Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at Upcoming Society for Immunotherapy of Cancer Annual Meeting October 05, 2022 From Navidea Biopharmaceuticals, Inc. Via Business Wire Navidea Biopharmaceuticals Appoints Joshua Wilson to the Board of Directors; Announces Dates Related to its 2022 Annual Meeting of Stockholders September 30, 2022 From Navidea Biopharmaceuticals, Inc. Via Business Wire Why ZW Data Action Technologies Jumped 37%; Here Are 71 Biggest Movers From Yesterday September 16, 2022 Gainers Via Benzinga Navidea Biopharmaceuticals Announces Presentation of Results from its Two Phase 2B Clinical Trials in Rheumatoid Arthritis at Upcoming American College of Rheumatology Annual Meeting September 15, 2022 From Navidea Biopharmaceuticals, Inc. Via Business Wire Why Adobe Is Trading Lower By 17%, Here Are 49 Stocks Moving In Thursday's Mid-Day Session September 15, 2022 Gainers HeartBeam, Inc. (NASDAQ: BEAT) shares surged 58% to $1.96 after the company announced its patent for a 12-lead electrocardiogram patch monitor intended for detection of acute coronary syndrome... Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday September 14, 2022 We're starting off Wednesday with an overview of the biggest pre-market stock movers this morning and the news moving those shares! Via InvestorPlace Why Kaspien Holdings Is Trading Lower By 13%; Here Are 21 Stocks Moving Premarket September 14, 2022 Gainers Aditxt, Inc. (NASDAQ: ADTX) rose 54.3% to $28.56 in pre-market trading following effect of 1:50 reverse stock split. Via Benzinga Navidea Biopharmaceuticals Announces Opening of Nine New Sites in its Pivotal Phase 3 Trial in Rheumatoid Arthritis and Termination of Binding Memorandum of Understanding with Jubilant Radiopharma September 01, 2022 From Navidea Biopharmaceuticals, Inc. Via Business Wire Navidea Biopharmaceuticals Announces Oral Ruling in Case Involving Attorney’s Fees September 01, 2022 From Navidea Biopharmaceuticals, Inc. Via Business Wire Navidea Biopharmaceuticals Announces Closing of its Rights Offering and Second Quarter 2022 Earnings Conference Call and Business Update August 30, 2022 From Navidea Biopharmaceuticals, Inc. Via Business Wire Navidea Biopharmaceuticals Announces Subscriptions of Approximately $14.2 Million from its Rights Offering August 25, 2022 From Navidea Biopharmaceuticals, Inc. Via Business Wire Short Volatility Alert: Navidea Biopharmaceuticals, Inc. August 24, 2022 On Tuesday, shares of Navidea Biopharmaceuticals, Inc. (NYSE: NAVB) experienced volatile short activity. After the activity, the stock price went up +0.00% to $0.39. The overall sentiment for NAVB has... Via Benzinga Navidea Biopharmaceuticals Announces Extension of Subscription Period to August 24, 2022 and Updated Terms of its Previously Announced Rights Offering August 18, 2022 From Navidea Biopharmaceuticals, Inc. Via Business Wire Stocks That Hit 52-Week Lows On Thursday August 18, 2022 During Thursday's trading, 62 companies set new 52-week lows. Via Benzinga Stocks That Hit 52-Week Lows On Tuesday August 16, 2022 On Tuesday, 37 stocks hit new 52-week lows. Via Benzinga Navidea Biopharmaceuticals Reports Second Quarter 2022 Financial Results August 15, 2022 From Navidea Biopharmaceuticals, Inc. Via Business Wire Navidea Biopharmaceuticals Announces Commencement of Rights Offering Subscription Period and Updated Terms of its Previously Announced Rights Offering August 04, 2022 From Navidea Biopharmaceuticals, Inc. Via Business Wire Navidea Biopharmaceuticals Announces Publication of Study Examining Use of Tc99m Tilmanocept for Lymphatic Mapping and Sentinel Lymph Node Biopsy in Melanoma and Oral Cancer in Australia August 01, 2022 From Navidea Biopharmaceuticals, Inc. Via Business Wire Navidea Biopharmaceuticals Reminds Investors of Today’s Deadline to be a Shareholder of Record for the Previously Announced Rights Offering August 01, 2022 From Navidea Biopharmaceuticals, Inc. Via Business Wire < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.